GS-7977

Gilead Shares Hit All-Time High On Positive Trial For Hep C Drug

Gilead Shares Hit All-Time High On Positive Trial For Hep C Drug

Yahoo/Investors Business Daily

Gilead Climbs on Study Results of Hepatitis C Combo

Gilead Climbs on Study Results of Hepatitis C Combo

Bloomberg

5 Things to Watch This Week in the Health-Care Sector

5 Things to Watch This Week in the Health-Care Sector

Motley Fool

Gilead Sciences Makes Headlines With HIV Prevention Pill, Looks to Hepatitis Drugs for Future

Gilead Sciences Makes Headlines With HIV Prevention Pill, Looks to Hepatitis Drugs for Future

Minyanville

Guilt by Association = 30% Slaughter?

Guilt by Association = 30% Slaughter?

Motley Fool

Forget the Numbers, This Pipeline Is King

Forget the Numbers, This Pipeline Is King

Motley Fool

Gilead Begins Single Pill Hepatitis C Study For 2014 Approval

Gilead Begins Single Pill Hepatitis C Study For 2014 Approval

Bloomberg

Bristol CEO says Gilead holding out on hep C tie-up

Bristol CEO says Gilead holding out on hep C tie-up

Fierce Biotech

Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations

Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations

Seeking Alpha